These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 21189350)

  • 1. Novel bacterial NAD+-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivo.
    Mills SD; Eakin AE; Buurman ET; Newman JV; Gao N; Huynh H; Johnson KD; Lahiri S; Shapiro AB; Walkup GK; Yang W; Stokes SS
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1088-96. PubMed ID: 21189350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic assessment of DNA ligase as an antibacterial target in Staphylococcus aureus.
    Podos SD; Thanassi JA; Pucci MJ
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4095-102. PubMed ID: 22585221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and characterization of an inhibitor specific to bacterial NAD+-dependent DNA ligases.
    Meier TI; Yan D; Peery RB; McAllister KA; Zook C; Peng SB; Zhao G
    FEBS J; 2008 Nov; 275(21):5258-71. PubMed ID: 18795946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of bacterial NAD+-dependent DNA ligase inhibitors: optimization of antibacterial activity.
    Stokes SS; Huynh H; Gowravaram M; Albert R; Cavero-Tomas M; Chen B; Harang J; Loch JT; Lu M; Mullen GB; Zhao S; Liu CF; Mills SD
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4556-60. PubMed ID: 21719282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of NAD(+) -dependent DNA ligase of mycobacteria as a potential target for antibiotics.
    Korycka-Machala M; Rychta E; Brzostek A; Sayer HR; Rumijowska-Galewicz A; Bowater RP; Dziadek J
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2888-97. PubMed ID: 17548501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity.
    Surivet JP; Lange R; Hubschwerlen C; Keck W; Specklin JL; Ritz D; Bur D; Locher H; Seiler P; Strasser DS; Prade L; Kohl C; Schmitt C; Chapoux G; Ilhan E; Ekambaram N; Athanasiou A; Knezevic A; Sabato D; Chambovey A; Gaertner M; Enderlin M; Boehme M; Sippel V; Wyss P
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6705-11. PubMed ID: 23006603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tricyclic dihydrobenzoxazepine and tetracyclic indole derivatives can specifically target bacterial DNA ligases and can distinguish them from human DNA ligase I.
    Yadav N; Khanam T; Shukla A; Rai N; Hajela K; Ramachandran R
    Org Biomol Chem; 2015 May; 13(19):5475-87. PubMed ID: 25875403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycobacterium tuberculosis NAD+-dependent DNA ligase is selectively inhibited by glycosylamines compared with human DNA ligase I.
    Srivastava SK; Dube D; Tewari N; Dwivedi N; Tripathi RP; Ramachandran R
    Nucleic Acids Res; 2005; 33(22):7090-101. PubMed ID: 16361267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cloning and functional characterization of an NAD(+)-dependent DNA ligase from Staphylococcus aureus.
    Kaczmarek FS; Zaniewski RP; Gootz TD; Danley DE; Mansour MN; Griffor M; Kamath AV; Cronan M; Mueller J; Sun D; Martin PK; Benton B; McDowell L; Biek D; Schmid MB
    J Bacteriol; 2001 May; 183(10):3016-24. PubMed ID: 11325928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New class of bacterial phenylalanyl-tRNA synthetase inhibitors with high potency and broad-spectrum activity.
    Beyer D; Kroll HP; Endermann R; Schiffer G; Siegel S; Bauser M; Pohlmann J; Brands M; Ziegelbauer K; Haebich D; Eymann C; Brötz-Oesterhelt H
    Antimicrob Agents Chemother; 2004 Feb; 48(2):525-32. PubMed ID: 14742205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure based identification of first-in-class fragment inhibitors that target the NMN pocket of M. tuberculosis NAD
    Shukla A; Afsar M; Kumar N; Kumar S; Ramachandran R
    J Struct Biol; 2021 Mar; 213(1):107655. PubMed ID: 33197566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification through structure-based methods of a bacterial NAD(+)-dependent DNA ligase inhibitor that avoids known resistance mutations.
    Murphy-Benenato K; Wang H; McGuire HM; Davis HE; Gao N; Prince DB; Jahic H; Stokes SS; Boriack-Sjodin PA
    Bioorg Med Chem Lett; 2014 Jan; 24(1):360-6. PubMed ID: 24287382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negishi cross-coupling enabled synthesis of novel NAD(+)-dependent DNA ligase inhibitors and SAR development.
    Murphy-Benenato KE; Gingipalli L; Boriack-Sjodin PA; Martinez-Botella G; Carcanague D; Eyermann CJ; Gowravaram M; Harang J; Hale MR; Ioannidis G; Jahic H; Johnstone M; Kutschke A; Laganas VA; Loch JT; Miller MD; Oguto H; Patel SJ
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5172-7. PubMed ID: 26463129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents.
    Eakin AE; Green O; Hales N; Walkup GK; Bist S; Singh A; Mullen G; Bryant J; Embrey K; Gao N; Breeze A; Timms D; Andrews B; Uria-Nickelsen M; Demeritt J; Loch JT; Hull K; Blodgett A; Illingworth RN; Prince B; Boriack-Sjodin PA; Hauck S; MacPherson LJ; Ni H; Sherer B
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1240-6. PubMed ID: 22183167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.
    Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Optimization of NAD+-Dependent DNA Ligase Inhibitors as Novel Antibacterial Compounds.
    Bi F; Ma R; Ma S
    Curr Pharm Des; 2017; 23(14):2117-2130. PubMed ID: 27784238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a novel and potent class of FabI-directed antibacterial agents.
    Payne DJ; Miller WH; Berry V; Brosky J; Burgess WJ; Chen E; DeWolf WE; Fosberry AP; Greenwood R; Head MS; Heerding DA; Janson CA; Jaworski DD; Keller PM; Manley PJ; Moore TD; Newlander KA; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Salyers KL; Seefeld MA; Smyth MG; Takata DT; Uzinskas IN; Vaidya K; Wallis NG; Winram SB; Yuan CC; Huffman WF
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3118-24. PubMed ID: 12234833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
    Hoover J; Lewandowski T; Straub RJ; Novick SJ; DeMarsh P; Aubart K; Rittenhouse S; Zalacain M
    Antimicrob Agents Chemother; 2016 Jan; 60(1):180-9. PubMed ID: 26482300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The kinetic mechanism of S. pneumoniae DNA ligase and inhibition by adenosine-based antibacterial compounds.
    Jahić H; Liu CF; Thresher J; Livchak S; Wang H; Ehmann DE
    Biochem Pharmacol; 2012 Sep; 84(5):654-60. PubMed ID: 22743594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1376-83. PubMed ID: 16569855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.